Effect of Remimazolam on Postoperative Nausea and Vomiting

• Status: Recruiting
• Trial end date: 2024-04-12
• Target enrollment: 0
• Participant gender: Female

Summary

The present trial is to study the effect of low dose remimazolam on postoperative nausea and vomiting (PONV) in patients at risks of PONV (women, postoperative use of opioid, nonsmokers) undergoing laparoscopic cholecystectomy.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Inje University

Criteria

Inclusion Criteria:

• women undergoing laparoscopic cholecystectomy under general anesthesia.

Exclusion Criteria:

• moderate to severe liver dysfunction (total bilirubin ≧ 3.0 mg/dL / aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧ 2.5 times more than normal range)

• moderate to severe renal dysfunction (serum creatinine ≧ 2.0 mg/dL / end-stage renal disease undergoing hemodialysis)

• tolerance to benzodiazepines

• hypersensitivity to anesthetic drugs (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Flumazenil)

• acute angle glaucoma

• alcohol dependence

• Galactose intolerance, Lactase deficiency, glucose-galactose malabsorption

• pregnant, breast feeding women

• BMI >35 kg/m2

• uncontrolled diabetes mellitus